Innate Pharma

Regulatory Filings • Apr 29, 2010

INNATE PHARMA ANNOUNCES THE RELEASE OF ITS ANNUAL REPORT AND REFERENCE DOCUMENT (IN FRENCH)

Marseilles, France, April 29, 2010

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that the French version of the 2009 Reference Document, including the Annual Financial Report, as well as the 2009 Annual Report of the Company, is available on its website (www.innate-pharma.com).

The Reference Document of the Company (in French) is also available on the website of the AMF, the French stock-market authorities (www.amf-france.org).

The English version of the 2009 Reference Document will be made available on Innate Pharma's website at the end of May 2010.

Hard copies of these documents are available upon request to the investor relations department of the Company.

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases. The Company was incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006. The Company has two drug candidates currently in Phase II clinical trials. Two of its preclinical programs are out-licensed to Novo Nordisk A/S.

Innate Pharma is based in Marseilles, France, and had 80 employees as at December 31, 2009.

Learn more about Innate-Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Laure-Hélène Mercier Director, Investor Relations Phone: +33 (0)4 30 30 30 87 Mobile: +33 (0)6 64 18 99 59 investors@innate-pharma.com caroline@alizerp.com

Innate Pharma Alize Public Relations Caroline Carmagnol Phone: +33 (0)1 42 68 86 40